Skip to main content

Articles

Page 34 of 34

  1. Diffusion imaging has demonstrated sensitivity to structural brain changes in Alzheimer’s disease (AD). However, there remains a need for a more complete characterization of microstructural alterations occurri...

    Authors: Emilie T. Reas, Donald J. Hagler Jr, Nathan S. White, Joshua M. Kuperman, Hauke Bartsch, Karalani Cross, Richard Q. Loi, Akshara R. Balachandra, M. J. Meloy, Christina E. Wierenga, Douglas Galasko, James B. Brewer, Anders M. Dale and Linda K. McEvoy
    Citation: Alzheimer's Research & Therapy 2017 9:55
  2. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimo...

    Authors: Ruth Stephen, Yawu Liu, Tiia Ngandu, Riitta Antikainen, Juha Hulkkonen, Juha Koikkalainen, Nina Kemppainen, Jyrki Lötjönen, Esko Levälahti, Riitta Parkkola, Pauliina Pippola, Juha Rinne, Timo Strandberg, Jaakko Tuomilehto, Ritva Vanninen, Miia Kivipelto…
    Citation: Alzheimer's Research & Therapy 2019 11:53
  3. A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer’s disease (AD).

    Authors: Piotr Lewczuk, Natalia Ermann, Ulf Andreasson, Christian Schultheis, Jana Podhorna, Philipp Spitzer, Juan Manuel Maler, Johannes Kornhuber, Kaj Blennow and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2018 10:71
  4. Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safet...

    Authors: Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli…
    Citation: Alzheimer's Research & Therapy 2017 9:95

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:99

  5. Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been established as “AD signature”. To what e...

    Authors: Paula M. Petrone, Adrià Casamitjana, Carles Falcon, Miquel Artigues, Grégory Operto, Raffaele Cacciaglia, José Luis Molinuevo, Verónica Vilaplana and Juan Domingo Gispert
    Citation: Alzheimer's Research & Therapy 2019 11:72
  6. Alzheimer’s disease is characterized by aggregated β-amyloid and tau proteins, but the clinical presentations and patterns of brain atrophy vary substantially. A part of this heterogeneity may be linked to the...

    Authors: Niklas Mattsson, Rik Ossenkoppele, Ruben Smith, Olof Strandberg, Tomas Ohlsson, Jonas Jögi, Sebastian Palmqvist, Erik Stomrud and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2018 10:77
  7. In a research study, to give a comprehensive evaluation of the impact of interventions, the outcome measures should reflect the lived experience of the condition. In dementia studies, this necessitates the use...

    Authors: Jennifer Kirsty Harrison, Anna H. Noel-Storr, Nele Demeyere, Emma L. Reynish and Terry J. Quinn
    Citation: Alzheimer's Research & Therapy 2016 8:48
  8. The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal compleme...

    Authors: Lutz Frölich, Oliver Peters, Piotr Lewczuk, Oliver Gruber, Stefan J. Teipel, Hermann J. Gertz, Holger Jahn, Frank Jessen, Alexander Kurz, Christian Luckhaus, Michael Hüll, Johannes Pantel, Friedel M. Reischies, Johannes Schröder, Michael Wagner, Otto Rienhoff…
    Citation: Alzheimer's Research & Therapy 2017 9:84
  9. Retinal imaging may serve as an alternative approach to monitor brain pathology in Alzheimer’s disease (AD). In this study, we investigated the association between retinal vascular and structural changes and c...

    Authors: S.Mojtaba Golzan, Kathryn Goozee, Dana Georgevsky, Alberto Avolio, Pratishtha Chatterjee, Kaikai Shen, Vivek Gupta, Roger Chung, Greg Savage, Carolyn F. Orr, Ralph N. Martins and Stuart L. Graham
    Citation: Alzheimer's Research & Therapy 2017 9:13
  10. Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical vali...

    Authors: Alberto Benussi, Antonella Alberici, Clarissa Ferrari, Valentina Cantoni, Valentina Dell’Era, Rosanna Turrone, Maria Sofia Cotelli, Giuliano Binetti, Barbara Paghera, Giacomo Koch, Alessandro Padovani and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2018 10:94
  11. Dementia is a substantial and increasing public health concern. Despite decades of research, a cure or effective preventative treatment for dementia remains elusive. We offer critical review of contemporary de...

    Authors: Craig W Ritchie, Graciela Muniz Terrera and Terence J Quinn
    Citation: Alzheimer's Research & Therapy 2015 7:31
  12. The progress we have made in understanding Alzheimer’s disease (AD) pathogenesis has led to the identification of several novel pathways and potential therapeutic targets. Rho GTPases have been implicated as c...

    Authors: Byron J. Aguilar, Yi Zhu and Qun Lu
    Citation: Alzheimer's Research & Therapy 2017 9:97
  13. Insulin resistance (IR) has previously been associated with an increased risk of developing Alzheimer’s disease (AD), although the relationship between IR and AD is not yet clear. Here, we examined the influen...

    Authors: Sarah Westwood, Benjamine Liu, Alison L. Baird, Sneha Anand, Alejo J. Nevado-Holgado, Danielle Newby, Maria Pikkarainen, Merja Hallikainen, Johanna Kuusisto, Johannes R. Streffer, Gerald Novak, Kaj Blennow, Ulf Andreasson, Henrik Zetterberg, Ulf Smith, Markku Laakso…
    Citation: Alzheimer's Research & Therapy 2017 9:31
  14. Variability in biological parameters has been reported to be associated with adverse health outcomes. We aimed to investigate the composite effect of the visit-to-visit variability in blood pressure, glucose, ...

    Authors: Seung-Hwan Lee, Kyungdo Han, Hanna Cho, Yong-Moon Park, Hyuk-Sang Kwon, Gunseog Kang, Kun-Ho Yoon and Mee Kyoung Kim
    Citation: Alzheimer's Research & Therapy 2018 10:110
  15. Alzheimer’s disease (AD) is recognized to have a long presymptomatic period, during which there is progressive accumulation of molecular pathology, followed by inexorable neuronal damage. The ability to identi...

    Authors: Philip S.J. Weston, Ivor J.A. Simpson, Natalie S. Ryan, Sebastien Ourselin and Nick C. Fox
    Citation: Alzheimer's Research & Therapy 2015 7:47
  16. Despite a tremendous amount of information on the role of amyloid in Alzheimer’s disease (AD), almost all clinical trials testing this hypothesis have failed to generate clinically relevant cognitive effects.

    Authors: Hugo Geerts, Athan Spiros and Patrick Roberts
    Citation: Alzheimer's Research & Therapy 2018 10:14
  17. This study was to investigate whether the previously proposed link between Alzheimer’s disease (AD) and decreased retinal nerve fiber layer thickness could be explained by the relationship between abnormal CSF...

    Authors: Eun Ji Lee, Tae-Woo Kim, Dae Seung Lee, Hyunjoong Kim, Young Ho Park, Jungeun Kim, Joon Woo Lee and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2016 8:6
  18. Alzheimer’s disease brains are characterized by extracellular plaques containing the aggregated amyloid β42 (Aβ42) peptide and intraneuronal tangles containing hyperphosphorylated tau. Aβ42 is produced by sequent...

    Authors: Simon Sjödin, Kerstin K. A. Andersson, Marc Mercken, Henrik Zetterberg, Herman Borghys, Kaj Blennow and Erik Portelius
    Citation: Alzheimer's Research & Therapy 2015 7:77